Press
Releases

Press Releases

June 29, 2021
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers Altimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programs Altimmune also provides an update on its T-COVID™  Phase 1/2 Clinical Trial
May 27, 2021
Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference
GAITHERSBURG, Md. , May 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference , being held June 1 - 4, 2021 .
May 11, 2021
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
GAITHERSBURG, Md. , May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021 . Altimmune management will host a conference call for investors
April 29, 2021
Altimmune to Present at Upcoming Scientific Conferences
GAITHERSBURG, Md. , April 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021 .
April 1, 2021
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
GAITHERSBURG, Md. , April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose
 

Investor Contact

Will Brown
Chief Financial Officer

Email: wbrown@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe